[1]曹晶,唐晓文,崔巍,等.移植前状态对难治复发急性淋巴细胞白血病异基因造血干细胞移植预后的影响[J].第三军医大学学报,2016,38(12):1374-1378.
 Cao Jing,Tang Xiaowen,Cui Wei,et al.Effect of disease status on outcome of allogeneic hematopoietic stem cell transplantation in treatment of refractory and relapsed acute lymphoblastic leukemia[J].J Third Mil Med Univ,2016,38(12):1374-1378.
点击复制

移植前状态对难治复发急性淋巴细胞白血病异基因造血干细胞移植预后的影响(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1374-1378
栏目:
专题报道
出版日期:
2016-06-30

文章信息/Info

Title:
Effect of disease status on outcome of allogeneic hematopoietic stem cell transplantation in treatment of refractory and relapsed acute lymphoblastic leukemia
作者:
曹晶唐晓文崔巍朱霞明孙爱宁仇惠英金正明苗瞄陈锋马骁薛胜利吴小津吴德沛
苏州大学附属第一医院江苏省血液研究所,卫生部血栓与止血重点实验室,血液学协同创新中心
Author(s):
Cao Jing Tang Xiaowen Cui Wei Zhu Xiaming Sun Aining Qiu Huiying Jin Zhengming Miao Miao Chen Feng Ma Xiao Xue Shengli Wu Xiaojin Wu Depei

Collaborative Innovation Center of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, China

关键词:
异基因造血干细胞移植难治复发急性淋巴细胞白血病缓解状态预后
Keywords:
allogeneic hematopoietic stem cell transplantation refractory/relapsed acute lymphoblastic leukemia status outcome
分类号:
R181.32; R617; R733.71
文献标志码:
A
摘要:

目的      探讨难治复发急性淋巴细胞白血病(acute lymphocytic leukemia,ALL)的缓解状态对异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)预后的影响。      方法      回顾性分析我研究所不同缓解状态下行allo-HSCT的52例难治复发ALL患者,其中19例处于未缓解(non-remission,NR)状态,33例达到第2次及以上完全缓解(complete remission,≥CR2)。所有患者均采用清髓性预处理,其中改良白消安加环磷酰胺37例,全身照射加环磷酰胺14例。      结果      除1例患者早期死亡外,其余51例均获得造血重建,NR和≥CR2患者100 d内移植相关死亡为10.5%和12.1%(P=1.000)。移植后急性移植物抗宿主病(graft versus host disease,GVHD)发生率为52.6%和57.6%(P=0.730),其中Ⅰ~Ⅱ度为42.1%和33.3%(P=0.527),Ⅲ~Ⅳ度为10.5%和24.3%(P=0.399),慢性GVHD发生率为41.6%和57.9%(P=0.660)。中位随访时间为12(1.8~44.5)个月,26例患者无白血病生存至今。NR与≥CR2患者的预计2年总生存(overall survival,OS)和无白血病生存(leukemia-free survival,LFS)分别为42.6%、45.7%(P=0.740)和46.3%、46.2%(P=0.998),累积复发率为47.0%、34.3%(P=0.425)。影响预后的单因素和多因素分析显示,移植前疾病缓解状态与生存无关,移植后发生慢性GVHD才是影响OS、LFS的独立预后因素。      结论      移植前NR患者与≥CR2患者相比,移植预后无统计学差异,提示allo-HSCT挽救性治疗NR状态下难治复发的ALL是可行的。

Abstract:

Objective      To determine the effect of disease status on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of patients with refractory and relapsed acute lymphoblastic leukemia (ALL).       Methods      Fifty-two patients with refractory and relapsed ALL, including 19 cases in non-remission (NR) and 33 cases in more than or equal to second complete remission (≥CR2) after allo-HSCT admitted in our department from January 2012 to June 2015 were enrolled in this study. All patients were treated with myeloablative conditioning. Of them, 37 cases received improved busulfan and cyclophosphamide treatment, and the left 14 cases total body irradiation plus cyclophosphamide.       Results      Beside 1 patient died early, the other 51 patients engrafted successfully. The transplantation-related mortality (TRM) within 100 d was 10.5% and 12.1% respectively for the NR and ≥CR2 groups (P=1.000). The incidence of acute graft versus host disease (aGVHD) was 52.6% and 57.6% (P=0.730), including 42.1% and 33.3% (P=0.527) with mild (grade Ⅰ~Ⅱ), and 10.5% and 24.3% (P=0.399) with severe (grade Ⅲ~Ⅳ). While, the incidence of cGVHD was 41.6% and 57.9% respectively for the 2 groups (P=0.660). During a median follow-up period of 12 (1.8~44.5) months, 26 patients were leukemia-free survival (LFS) till now. The estimated 2 year overall survival (OS) and 2 year LFS rate were 42.6% and 45.7% (P=0.740), and 46.3% and 46.2% (P=0.998) respectively, and the cumulative relapse rate was 47.0% and 34.3% (P=0.425) respectively in the NR and ≥CR2 groups. Multivariate and univariate analyses showed that the disease status had no effect on the OS after all-HSCT, and appearance of cGVHD was an independent prognostic factor for OS and LFS.       Conclusion      No significant difference is seen in the prognosis of allo-HSCT in the NR and ≥CR2 patients with refractory and relapsed ALL. Our results indicate that alIo-HSCT is an effective salvage therapy for the patients, and the overall outcome seems unrelated to the disease status (NR or CR) before transplantation.

参考文献/References:

[1]Tavernier E, Boiron J M, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial [J]. Leukemia, 2007, 21(9): 1907-1914. DOI: 10.1038/sj.leu.2404824
[2]于亚平. 成人急性淋巴细胞白血病治疗进展[J]. 现代肿瘤医学, 2009, 17(12): 2444-2448. DOI: 10.3969/j.issn.1672-4992.2009.12.076
[3]Blum W, Bolwell B J, Phillips G, et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation[J]. Biol Blood Marrow Transplant, 2006, 12(1): 61-67. DOI: 10.1016/j.bbmt.2005.06.004
[4]Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation[J]. Blood, 2008, 112(9): 3574-3581. DOI: 10.1182/blood-2008-02-140095
[5]黄晓军. 难治/复发白血病的造血干细胞移植[J]. 中华医学杂志, 2006, 86(32): 2240-2242. DOI: 10.3760/j: issn: 0376-2491.2006.32.003
[6]Horan J T, Logan B R, Agovi-Johnson M A, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?[J]. J Clin Oncol, 2011, 29(7): 805-813. DOI: 10.1200/jco.2010.32.5001
[7]李桥川, 章忠明, 刘练金, 等. 异基因外周血造血干细胞移植治疗急性淋巴细胞白血病95例疗效分析[J]. 中华器官移植杂志, 2015, 36(2): 82-86. DOI: 10.3760/cma.j.issn.0254-1785. 2015.02.005.
[8]Burke M J, Verneris M R, Le-Rademacher J, et al. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(12): 2154-2159. DOI: 10. 1016/j.bbmt.2015.08.023
[9]Biggs J C, Horowitz M M, Gale R P, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy[J]. Blood, 1992, 80(4): 1090-1093.
[10]Duval M, Klein J P, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure[J]. J Clin Oncol, 2010, 28(23): 3730-3738. DOI: 10. 1200/JCO.2010.28.8852
[11]Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(2): 266-274. DOI: 10.1016/j.bbmt.2014.10.021
[12]唐举贤, 朱康儿, 张涛, 等. 异基因造血干细胞移植治疗未缓解白血病的临床研究[J]. 中华血液学杂志, 2013, 34(3): 267-268. DOI: 10.3760/cma.j.issn.0253-2727.2013.03.021

更新日期/Last Update: 2016-06-07